Abivax also recently appointed industry veteran Mark Stenhouse as an advisor, a move expected to contribute significantly to the company's strategic direction. This decision reflects Abivax's commitment to leveraging industry experience to advance its clinical programs. Analysts from Guggenheim, Piper Sandler, and BTIG have all maintained a positive outlook on Abivax, emphasizing the potential of obefazimod. Guggenheim's rating follows a meeting with Abivax's management team, while Piper Sandler's Overweight rating is driven by upcoming developments related to obefazimod. BTIG maintains its Buy rating on Abivax based on recent preclinical data indicating that the combination of obefazimod with etrasimod shows a synergistic effect in reducing cytokine levels. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.